Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 6/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 6/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 5/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | PRKCG | P05129 | 2/20 | 1.00 |
| ▸ | PRKCB | P05771 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | PRKCH | P24723 | 2/20 | 1.00 |
| ▸ | PRKCI | P41743 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | FLT1 | P17948 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368635 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL29375761 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL145351 | 0.98 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL144578 | 0.94 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL144075 | 0.90 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL148438 | 0.89 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL143775 | 0.89 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL142058 | 0.89 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL145287 | 0.88 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL146740 | 0.88 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180291448-A1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-10-11 | — | — | US | claimed |
| EP-2951290-B1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) | US HEALTH (US) | 2017-11-29 | — | — | EP | claimed |
| EP-2951290-A2 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014121077-A2 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-08-07 | — | — | WO | claimed |
| EP-0790997-B1 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | claimed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | claimed |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340836-A1 | METHODS FOR PRODUCTION OF IPSCS | NEW YORK STEM CELL FOUND INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250197802-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250154467-A1 | CREATION OF VASCULARIZED BIOLOGICAL STRUCTURES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-05-15 | — | — | US | disclosed |
| US-12241083-B2 | Macs-based purification of stem cell-derived retinal pigment epithelium | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20040057950-A1 | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases | WAKSAL HARLAN W (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1080113-A4 | TREATMENT OF HUMAN TUMORS WITH RADIATION AND INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES | IMCLONE SYSTEMS INC (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1080113-A1 | TREATMENT OF HUMAN TUMORS WITH RADIATION AND INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES | IMCLONE SYSTEMS, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-0790997-B1 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999060023-A1 | TREATMENT OF HUMAN TUMORS WITH RADIATION AND INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES | IMCLONE SYSTEMS INCORPORATED (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | LGALS1, LGALS9, ALDH1A2 | FGFR1 499/4885FGFR2 1047/4885FGFR4 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.